Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

At a time when 45% of American women face significant barriers to reproductive care, Twentyeight Health is a telemedicine ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...